All schools in Upshur County will close at 1 p.m. today. All B-UHS sporting events today are canceled.

WVU IDEA Hub wins national rising star award for entrepreneurship and innovation

Richard L. Simmons Lecture in Surgical Science and Department of Surgery Research Day, group photo in front of Soldiers and Sailors, held at the University Club, Wednesday, May 11, 2016. Dr Avery Nathens, Timothy Billiar, Dr. Richard Simmons. 214102

If the American Cancer Society’s projections prove accurate, more people will die from pancreatic cancer than from breast, brain, ovarian or prostate cancer this year.

One reason pancreatic cancer is so lethal is its resistance to traditional chemotherapy. But West Virginia University surgical oncologist Brian Boone is exploring whether FOLFIRINOX—a new combination of cancer drugs—can improve outcomes in patients whose pancreatic cancer is “borderline resectable,” meaning that a tumor may be too close to a blood vessel to be removed safely.

“The way pancreatic tumors sit, they’re very close to several important blood vessels that you really can’t live without. That’s where chemotherapy comes into play,” said Boone, an assistant professor in the School of Medicine’s Department of Surgery. “We try to shrink the tumor off of the vein and change it from borderline resectable to resectable, or removable by surgery.”

In a recent meta-analysis of 24 studies, Boone and a team of researchers considered 313 cases of borderline resectable pancreatic cancer that physicians treated with FOLFIRINOX. They analyzed the patients’ overall survival rates. They also evaluated how frequently tumors shrank enough to be surgically removed. The team found that FOLFIRINOX prolonged patients’ lives, on average, and made surgery possible in more instances. Their findings appear in the Journal of the National Cancer Institute.

“There’s no control group, but when you compare it to what we’ve historically seen in patients that are borderline resectable and that we take straight to surgery, FOLFIRINOX resulted in better survival and better rates of resection,” Boone said.

More than two-thirds—or 67.8 percent—of the cancers included in the study responded well enough to FOLFIRINOX that they could be completely removed surgically. “Historically, complete removal of the tumor is accomplished in a far lower number of patients without treatment before surgery and often requires removal of a portion of the vein,” he said.

On average, patients who took FOLFIRINOX survived for 22.2 months overall. Without the drug, patients with borderline resectable cancer tend to survive for about 12 months, based on Boone’s clinical experience.

“There’s really been a paradigm shift for pancreatic cancer, now that we have better drugs,” he said.

Despite these improvements in treatment, pancreatic cancer is currently the fourth deadliest, and “it’s climbing the ladder in terms of the number of people it kills,” said Carl Schmidt, chief of the Surgical Oncology Division. “In my 10 years of being in practice, there’s been more interest in pancreatic cancer, but moving the needle is really hard.”

To that end, Boone, Schmidt and their colleagues are pursuing studies that span the laboratories where scientists conduct basic-science experiments, the infusion rooms where patients receive treatment and the operating rooms where oncologists perform surgery.

“We’re developing a full spectrum of pancreatic cancer research. That’s why we do the basic science: we’re identifying patients at the bedside and trying to find solutions in the lab,” Boone said. “And it’s all driven by trying to make outcomes better for patients that we take care of every day.”

Share this story:

Local Businesses

RECENT Stories

Wesleyan finishes seventh in MEC Commissioners Cup standings

West Virginia Wesleyan finished seventh in the 2024-25 Mountain East Conference Commissioner’s Cup standings, while the University of Charleston captured its eighth consecutive and tenth overall title for all-around athletic excellence.
Summer basketball

Summer basketball league wraps up week one

The Upshur County Summer Basketball League completed its first week at West Virginia Wesleyan College, featuring high-scoring performances from Dalton Hamrick, Cooper Sanders, Derek Sevier, Manadji Tokindang, and Austin Upton.
BUHS Girls Soccer Feature Image

Kelley calls soccer camp a success, has sights on leading B-U girls program to new heights

Logan Kelley, newly named head coach of the Buckhannon-Upshur Lady Buc soccer team, helped oversee a successful youth camp and aims to bring stability and new achievements to the girls program.

Wesleyan professor collecting first-hand accounts, photos to commemorate 1985 flood

A West Virginia Wesleyan College professor and librarian are collecting first-hand stories and photos from the 1985 flood to create an anniversary exhibit preserving campus and community memories of the disaster.

Pizza shop worker arrested for using customer credit card info to gamble online

A pizza shop employee was arrested after allegedly taking a customer’s credit card information from a food order and using it to make unauthorized bets totaling $300 on an online gambling site.

WVU Medicine St. Joseph’s Hospital and Rotary Club of Buckhannon-Upshur to hold blood drive on August 15

WVU Medicine St. Joseph’s Hospital and the Rotary Club of Buckhannon-Upshur will host a blood and food drive on August 15 at the Event Center at Brushy Fork, offering incentives for blood donors.

Buckhannon Water Board Agenda: July 10, 2025

The City of Buckhannon Water Board’s agenda for its July 10, 2025, meeting has been released by My Buckhannon.

Upshur County Commission Agenda: July 10, 2025

Here is the agenda for the Upshur County Commission meeting scheduled for July 10, 2025.

Really Really Free Market and Community Potluck scheduled for Sunday, July 13

A community Really Really Free Market and potluck will be held Sunday, July 13, from 1–3 pm at Walnut and Chestnut streets, featuring free goods, services, food and opportunities to connect and volunteer.